science wire

« BACK

Pharmacology



Results 1 - 50 of 1332.
1 2 3 4 5 ... 27 Next »


Pharmacology - Health - 19.08.2019
Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019
PARAGON-HF trial will provide Entresto (sacubitril/valsartan) Phase III full results in heart failure with preserved ejection fraction (HFpEF)   New PROVE-HF and EVALUATE-HF studies will highlight Entresto's direct impact on the heart in heart failure with reduced ejection fraction (HFrEF)   New PIONEER-HF and TRANSITION-HF findings will advance understanding of Entresto use in patients hospitalized for decompensated HFrEF following stabilizatio

Life Sciences - Pharmacology - 16.08.2019
Berkeley Talks transcript: Take an intoxicating plants tour at UC Botanical Garden
Sal Levinson: I'm Sal Levinson - I'm a propagator at the UC Botanical Garden. I work in native propagation, I grow plants that we sell here, and I also do the butterfly tours here.

Pharmacology - Health - 16.08.2019
FDA approves Roche’s RozlytrekTM (entrectinib) for people with ROS1-positive, metastatic non-small cell lung cancer and NTRK gene fusion-positive solid tumours
First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread to the brain Roche's first FDA-approved tumour-agnostic medicine Roche today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek?

Health - Pharmacology - 07.08.2019
Tiny biodegradable circuits for releasing painkillers inside the body
Tiny biodegradable circuits for releasing painkillers inside the body
EPFL researchers have developed biodegradable microresonators that can be heated locally with a wireless system.

Pharmacology - Life Sciences - 07.08.2019
Novartis stands behind Zolgensma (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
Basel, August 6, 2019 - Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma (onasemnogene abeparvovec-xioi). First and foremost, we are fully confident in the safety, quality and efficacy of Zolgensma. The FDA supports the continued marketing and use of Zolgensma for patients with spinal muscular atrophy (SMA) less than 2 years of age.

Pharmacology - Health - 05.08.2019
Roche’s Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer
IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in previously untreated advanced bladder cancer Data will be shared with health authorities globally, including

Career - Pharmacology - 05.08.2019

Pharmacology - Health - 30.07.2019
Yale and Mayo Clinic awarded FDA grant to study opioid prescribing and use
Yale University and Mayo Clinic have been awarded a grant for up to $5.3 million over two years by the U.S. Food and Drug Administration (FDA) to study patients' experiences with pain and use of opioids prescribed for acute pain. This project is part of the Center of Excellence in Regulatory Science and Innovation (CERSI) , a joint effort between Yale, Mayo Clinic, and the FDA.

Health - Pharmacology - 26.07.2019
Superbugs: A Pop-Up Science Shop (29th July - 11th August)
Ever wondered what micro-organisms are living on your skin? Drop into our interactive lab in the heart of Cardiff's busy shopping centre to find out, and you can even get pictures of them! Cardiff Un

Pharmacology - Health - 26.07.2019
Novartis receives positive CHMP opinion for Lucentis treatment
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Pha

Pharmacology - Health - 26.07.2019
CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy
Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years

Health - Pharmacology - 16.07.2019
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from stand

Pharmacology - Health - 09.07.2019
Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of

Health - Pharmacology - 28.06.2019
CHMP recommends EU approval of Tecentriq for people with breast cancer
Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive Phase III cancer immunother

Pharmacology - Administration - 28.06.2019
Sussex Drug Discovery Centre appoints Professor Jeffrey Hill as new Director
Professor Jeffrey Hill has been appointed as the new Director of the Sussex Drug Discovery Centre ( SDDC ) within the School of Life Sciences.

Health - Pharmacology - 28.06.2019
Ending needless chemotherapy for breast cancer
Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment. Breast cancer survivor Joy Jensen said such a test would give control back to those who felt helpless about their situation.

Pharmacology - Health - 26.06.2019
Long delays prescribing new antibiotics hinder market for needed drugs
U.S. hospitals wait over a year on average to begin prescribing newly developed antibiotics, a delay that might threaten the supply or discourage future development of needed drugs.

Health - Pharmacology - 24.06.2019
New centre to fight drug-resistant bugs through improving use of antibiotics
A new Imperial centre will pioneer research to optimise how antimicrobial drugs are used to both improve patient care and preserve antibiotics.

Pharmacology - Health - 21.06.2019
Protein hitch hiking into the cancer cell: the next generation of platinum drugs
Protein hitch hiking into the cancer cell: the next generation of platinum drugs
The young spin-off "P4 Therapeutics" was awarded with the "Der Brutkasten Media Award" An interdisciplinary team of the University of Vienna and the Medical University of Vienna has developed a new platinum compound with great potential as anticancer drug.

Pharmacology - Health - 20.06.2019
MND Global Day - UQ experts available
University of Queensland experts are available to comment on various issues relating to MND Global Day on Friday 21 June.

Health - Pharmacology - 18.06.2019
Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Ph

Health - Pharmacology - 17.06.2019
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria

Health - Pharmacology - 14.06.2019
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis   A

Health - Pharmacology - 14.06.2019
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001)
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C

Pharmacology - Health - 12.06.2019
Novartis Cosentyx first to show efficacy in all key manifestations of psoriatic arthritis
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide   66

Health - Pharmacology - 12.06.2019
Cosentyx provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg   Data at 2 years demonstrate over 50% of adults with active PsA achie

Pharmacology - 11.06.2019
Cause of hardening of the arteries - and potential treatment - identified
Cause of hardening of the arteries - and potential treatment - identified
Artery hardening happens to everyone as they age...but up until now we haven't known what controls this process and therefore how to treat it Melinda Duer New approach to drug discovery

Pharmacology - Health - 11.06.2019
FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?

Business / Economics - Pharmacology - 07.06.2019

Health - Pharmacology - 06.06.2019
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
1 2 3 4 5 ... 27 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |
 
/bin/cat /www/cms/admin/geodata/worldcitiespop.txt | egrep -ai '^,' > '/www/cms/admin/geodata/_cities.txt'